
The proposed deal could reach $3.4 billion, including cash and payments tied to milestones for Ollin’s experimental eye drug.
Johnson & Johnson is in advanced talks to acquire Ollin Biosciences in a deal that could be worth up to $3.4 billion, according to Dünya. No final agreement has been announced, and the discussions could still fall through.
The proposed terms include $2.2 billion in cash for Ollin shareholders and up to $1.2 billion in payments tied to development milestones. The deal centers on OLN324, an experimental treatment for two retinal diseases that has not received regulatory approval.
As of Friday’s close, Johnson & Johnson shares were at $285.75, up 0.79% from the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.